Groupe d'Etude en Oncologie du Quebec

Titre	The predictive value of coexisting TMPRSS2-ERG gene fusion and PTEN deletion in prostate cancer patients with biochemical failure status post salvage or radical radiation therapy
Protocole ID	PCS VIII
ClinicalTrials.gov ID	NCT02573636
Type(s) de cancer	Prostate
Phase	Autres
Institution	CISSS DE LAVAL HOPITAL DE LA CITE-DE-LA-SANTE 1755 boul. René-Laennec, Laval, QC, H7M 3L9
Ville	Laval
Investigateur(trice) principal(e)	Dr Levon Igidbashian
Coordonnateur(trice)	Solange Tremblay 450-668-1010 poste 23603
Statut	Actif en recrutement
Date d'activation	26-07-2016
Critètes d'éligibilité	Patients with adenocarcinoma of the prostate, status post-radical radiation therapy or salvage radiation therapy, who have biochemical failure (rising PSA) or not (matched control group), and meets one of the following criteria at the time of the original diagnosis: T3a + PSA > 20 Gleason 8 or higher Karnofsky performance status ≥ 70. Signed study-specific informed consent
Critètes d'exclusion

Groupe d'étude en oncologie du Québec